alexa Could Diagnostic Biomarkers Be Used To Predict The Response To Biologic Therapy In Rheumatoid Arthritis?
ISSN: 2476-2067

Toxicology: Open Access
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

8th World Congress on Toxicology and Pharmacology
April 13-15, 2017 Dubai, UAE

Gavrila B I, Claudia Ciofu, Carina Mihai, Bojinca M, Stoica V, Gabriela Udrea, Ciotaru D, Mihaela Surcel, Adrina Munteanu, Ursaciuc C and Eugenia Panaitescu
Carol Davila University of Medicine and Pharmacy, Romania
INCD, Romania
ScientificTracks Abstracts: Toxicol Open Access
DOI: 10.4172/2476-2067.C1.002
Abstract
Background: Biologic therapies have revolutionized the treatment of Rheumatoid Arthritis (RA). Despite these advances, 20-40% of the patients are declared nonresponders to at least one of the therapies. The patient exposure to the potential side effects and high costs requires the discovery of a biomarker that could identify those who can benefit from the pretreatment of a certain therapy. We proposed to test the predictive role for the response to biologic therapy of diagnostic biomarkers used in RA: rheumatoid factor (RF) isotypes IgM and IgA, anti-cyclic citrullinated peptide (anti-CCP) and auto-antibodies against mutated citrullinated vimentin (anti-MCV). We also followed the evolution of serum levels of these biomarkers under biologic therapy. Methods: Prospective and observational study including 64 patients followed 12 months with active RA, uncontrolled by conventional synthetic DMARDs or declared non-responders to one of the biologic DMARDs. Results: Lower baseline titres of RF type Ig M (51.36±95.359 U/ml, p=0.01629), Ig A (22.45±61.256 U/ml, p=0.03336) and anti-CCP (60.82±26.331ng/ml, p=0.00011) had predictive value for achieving a good EULAR response at 6 months. Regarding anti-MCV baseline titres, there were no differences between groups at 6 months (p=0.45914) or at 12 months (p=0.11354). Grouping patients in 2 categories (responders/non-responders), we identified significant differences between groups only for anti-CCP and response at 6 months (responders 96.04±50.355ng/ml, non-responders 146.16±41.68ng/ml, p=0.02834). For the EULAR response at 12 months, lower baseline titres for RF type Ig M (92.93±120.22 U/ml, p=0.01032) and Ig A (49.96±98.08 U/ml, p=0.00247) had predictive value for achieving a good response at 12 months. We didn’t obtain other information grouping patients in 2 categories. Regarding the evolution of serum levels, we noticed a reduction for all four biomarkers tested, statistically significant at 6 and / or 12 months from baseline. Conclusion: Besides from their diagnostic role, these biomarkers could be used for other purposes in Rheumatoid Arthritis.
Biography

Gavrilă B I completed his PhD in 2016 from University of Medicine and Pharmacy, Bucharest (Romania). Currently, he is working as an Assistant Professor at Department of Internal Medicine and Rheumatology, Bucharest.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords